ARCTURUS THERAPEUTICS HOLDINGS INC. Cash and Restricted Cash
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) had Cash and Restricted Cash of $193.51 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $193.51M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $213.40M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $232.79M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $237.25M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $193.51M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $213.40M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $232.79M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $237.25M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $253.35M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $273.83M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $293.91M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $294.06M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $317.21M 10-Q · filed 2025-08-11 |
| 2024-03-31 | $345.28M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $348.89M 10-K · filed 2026-03-03 |
| 2023-09-30 | $369.05M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $380.60M 10-Q · filed 2024-08-05 |
| 2023-03-31 | $330.05M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $393.98M 10-K · filed 2026-03-03 |
| 2022-09-30 | $239.76M 10-Q · filed 2023-11-14 |
| 2022-06-30 | $285.57M 10-Q · filed 2023-08-07 |
| 2022-03-31 | $321.75M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $372.57M 10-K · filed 2025-03-06 |
| 2021-09-30 | $415.95M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $433.68M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $466.95M 10-Q · filed 2022-05-09 |
| 2020-12-31 | $463.00M 10-K · filed 2024-03-14 |
| 2020-09-30 | $307.13M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $136.22M 10-Q · filed 2021-08-10 |
| 2020-03-31 | $59.58M 10-Q · filed 2021-05-10 |
| 2019-12-31 | $71.46M 10-K · filed 2022-03-01 |
| 2019-09-30 | $74.28M 10-Q · filed 2020-11-09 |
| 2019-06-30 | $55.95M 10-Q · filed 2020-08-10 |
| 2019-03-31 | $31.33M 10-Q · filed 2020-05-08 |
| 2018-12-31 | $36.82M 10-K · filed 2022-03-01 |
| 2018-09-30 | $30.44M 10-Q · filed 2019-11-08 |
| 2018-06-30 | $29.43M 10-Q · filed 2019-08-14 |
| 2017-12-31 | $25.24M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |